Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Chemomab Therapeutics Ltd. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- −2 vs. Q1 2026
- Shares held
- 379.8K
- +28.3K (+8.0%) vs. Q1 2026
- Total value
- $615.3K
- +$63.4K (+11.5%) vs. Q1 2026
- New holders
- 1
- 4 more added
- Sold out
- 3
- 4 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $615.3K |
| Q1 2026 | 15 | $551.9K |
| Q4 2025 | 14 | $606.1K |
| Q3 2025 | 10 | $1.03M |
| Q2 2025 | 14 | $4.91M |
| Q1 2025 | 17 | $4.07M |
| Q4 2024 | 16 | $7.53M |
| Q3 2024 | 15 | $7.14M |
| Q2 2024 | 15 | $2.44M |
| Q1 2024 | 14 | $2.08M |
| Q4 2023 | 16 | $1.47M |
| Q3 2023 | 11 | $2.26M |
| Q2 2023 | 11 | $3.33M |
| Q1 2023 | 13 | $4.56M |
| Q4 2022 | 14 | $10.6M |
| Q3 2022 | 15 | $8.09M |
| Q2 2022 | 13 | $12.2M |
| Q1 2022 | 15 | $15.9M |
| Q4 2021 | 14 | $22.7M |
| Q3 2021 | 15 | $35.9M |
| Q2 2021 | 12 | $59.5M |
| Q1 2021 | 10 | $82.6M |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Chemomab Therapeutics Ltd.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 95,311 | $154.4K | 0.00% | +31,129+48.5% | Added |
| ADAR1 Capital Management, LLC | 80,000 | $129.6K | 0.01% | 00.0% | Unchanged |
| Kestra Private Wealth Services, LLC | 61,710 | $100.0K | 0.00% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 51,793 | $83.9K | 0.01% | 00.0% | Unchanged |
| Rhumbline Advisers | 30,529 | $49.5K | 0.00% | +12,163+66.2% | Added |
| XTX Topco Ltd | 15,987 | $25.9K | 0.00% | −2,642−14.2% | Reduced |
| Philadelphia Investment Partners, LLC | 15,000 | $24.3K | 0.02% | +6,800+82.9% | Added |
| Lido Advisors, LLC | 14,341 | $23.2K | 0.00% | +14,341 | New |
| BNP Paribas Arbitrage, SA | 6,805 | $11.0K | 0.00% | −1,620−19.2% | Reduced |
| GAMMA Investing LLC | 4,740 | $7.68K | 0.00% | −2,839−37.5% | Reduced |
| Morgan Stanley | 3,575 | $5.79K | 0.00% | −1,000−21.9% | Reduced |
| SBI Securities Co., Ltd. | 34 | $55 | 0.00% | +6+21.4% | Added |
| Caitong International Asset Management Co., Ltd | 8 | $13 | 0.00% | 00.0% | Unchanged |
| SmartHarvest Portfolios, LLC | 0 | $0 | 0.00% | −14,566−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −13,491−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −8−100.0% | Sold out |